GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » Current Ratio

XBiotech (XBiotech) Current Ratio : 33.07 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is XBiotech Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. XBiotech's current ratio for the quarter that ended in Dec. 2023 was 33.07.

XBiotech has a current ratio of 33.07. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for XBiotech's Current Ratio or its related term are showing as below:

XBIT' s Current Ratio Range Over the Past 10 Years
Min: 4.64   Med: 16.62   Max: 81.8
Current: 33.07

During the past 12 years, XBiotech's highest Current Ratio was 81.80. The lowest was 4.64. And the median was 16.62.

XBIT's Current Ratio is ranked better than
97.3% of 1555 companies
in the Biotechnology industry
Industry Median: 3.77 vs XBIT: 33.07

XBiotech Current Ratio Historical Data

The historical data trend for XBiotech's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech Current Ratio Chart

XBiotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.90 81.80 71.49 54.07 33.07

XBiotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.07 59.78 47.08 38.61 33.07

Competitive Comparison of XBiotech's Current Ratio

For the Biotechnology subindustry, XBiotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XBiotech's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XBiotech's Current Ratio distribution charts can be found below:

* The bar in red indicates where XBiotech's Current Ratio falls into.



XBiotech Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

XBiotech's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=201.718/6.1
=33.07

XBiotech's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=201.718/6.1
=33.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XBiotech  (NAS:XBIT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


XBiotech Current Ratio Related Terms

Thank you for viewing the detailed overview of XBiotech's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XBiotech (XBiotech) Business Description

Traded in Other Exchanges
Address
5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Executives
Angela Hu officer: Principle Financial Officer 5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard director, 10 percent owner 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a. 10 percent owner MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie director, 10 percent owner 735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy officer: VP of R&D 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han officer: VP of Fin & HR, Secretary 8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut 10 percent owner CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby director 109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes 10 percent owner RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam director 56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin director 77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman officer: Sr.VP Corp. Strategy & Finance 8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson officer: VP of Commercial Development 8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury officer: VP of Business Development 8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough officer: VP Clinical Operations 115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703

XBiotech (XBiotech) Headlines

From GuruFocus

XBiotech to Launch Novel Candidate Therapy for Stroke

By Marketwired Marketwired 10-28-2021

XBiotech Inks Clinical Manufacturing Deal

By GuruFocusNews GuruFocusNews 02-02-2022

XBiotech to Launch Novel Candidate Therapy for Stroke

By GlobeNewswire GlobeNewswire 10-28-2021